Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04683003 · ClinicalTrials.gov registry record · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
A Phase 3 study of Thrombotic Thrombocytopenic Purpura (TTP), sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 77
- Enrollment target
- 20
- Study locations
NCT04683003 is a Phase 3 study of Thrombotic Thrombocytopenic Purpura (TTP) that is actively recruiting participants, run by Takeda. The registered enrollment target is 77 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04683003, a Phase 3 study of Thrombotic Thrombocytopenic Purpura (TTP), is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 77 participants
- Enrollment target
- 20
- Study locations
Study Summary
Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can also occur. People who have TTP may bleed underneath the skin forming purple bruises, or purpura. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them, leading to fewer red blood cells than in normal. TTP is caused by a lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in controlling clotting of the blood. The ADAMTS13 enzyme breaks up another blood protein called von Willebrand factor that forms blood clots by clumping together with platelets. Some people are born with this condition, while others develop the condition during their life. Many people who are born with TTP experience frequent flare-ups that need to be treated right away. TAK-755 is a medicine that replaces ADAMTS13 and may prevent or control TTP flare-ups, called acute TTP events. The main aim of the study is to check for side effects of long-term treatment with TAK-755. Treatment will be given in 2 ways: 1. TAK-755 treatment given either every week or every other week to prevent acute TTP events from happening (the "prophylactic" cohort). 2. TAK-755 treatment given to control an acute TTP event when it happens (the "on-demand" cohort). Participants in the prophylactic cohort will receive treatment in the clinic or at home for up to approximately 3 years. They will visit the clinic at least every 12 weeks. Participants in the on-demand cohort will receive daily treatment for the acute TTP event until the flare-up has gotten better. They will
Conditions Studied
Interventions
- BIOLOGICAL TAK-755
Study Locations (20)
Other
- AKH - Medizinische Universität Wien - Vienna
- Hôpital Saint-Antoine - Paris
- Hôpital Robert Debré- Paris - Paris
- Universitaetsklinikum Hamburg-Eppendorf - Hamburg
- Universitaetsklinikum Jena, Klinik fuerKinder-und Jugendmedizin - Jena
Beijing Municipality
- Beijing Children's Hospital - Beijing
- Peking Union Medical College Hospital - Beijing
Hubei
- Tongji Hospital Affiliated to Tongji Medicine University - Wuhan
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII) - Bergamo
Georgia
- Childrens Healthcare of Atlanta - Atlanta
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
North Carolina
- Duke University Medical Center - Durham
Ohio
- Mid Ohio Heart Clinic Inc - Dublin
Oklahoma
- University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2027-03-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04683003
The ClinicalTrials.gov registry entry for NCT04683003 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombotic Thrombocytopenic Purpura (TTP) appearing as the primary indexed condition, and to 1 intervention - of which TAK-755 is the first listed.
NCT04683003 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Beijing Municipality, Hubei.
Frequently Asked Questions
What is clinical trial NCT04683003 about?
NCT04683003 is a clinical study titled "A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura". Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can de...
What is the current status of trial NCT04683003?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 77 participants. The study started on 2021-04-14. Estimated completion is 2027-03-16.
What conditions does trial NCT04683003 study?
This clinical trial studies the following conditions: Thrombotic Thrombocytopenic Purpura (TTP).
What interventions are being tested in trial NCT04683003?
The interventions under investigation include: TAK-755 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04683003?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04683003 being conducted?
This trial has 20 study locations across Georgia, New York, North Carolina, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombotic Thrombocytopenic Purpura (TTP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.